Acinetobacter baumannii (A. baumannii) is undoubtedly one of the most successful
pathogens in the modern healthcare system. With invasive procedures, antibiotic use and …

Acinetobacter baumannii has emerged as a highly troublesome pathogen for many
institutions globally. As a consequence of its immense ability to acquire or upregulate …

We may soon be facing the end of the “antibiotic era.” The initial and seemingly unstoppable
success of antibiotics, the fruit of human ingenuity, has been countered by an escalation of …

Institutional outbreaks caused by Acinetobacter baumannii strains that have acquired
multiple mechanisms of antimicrobial drug resistance constitute a growing public-health …

The emergence of multidrug-resistant (MDR) Gram-negative bacilli creates a challenge in
the treatment of nosocomial infections. While the pharmaceutical pipeline is waning, two …

Acinetobacter baumannii resistance to carbapenem antibiotics is a serious clinical
challenge. As a newly developed technology, silver nanoparticles (AgNPs) show some …

Tigecycline (TIG) exhibits broad-spectrum activity against many Gram-positive and Gram-
negative pathogens. However, clinical resistance has emerged recently and has been …

Acinetobacter meningitis is becoming an increasingly common clinical entity, especially in
the postneurosurgical setting, with mortality from this infection exceeding 15%. Infectious …

Complicated intra-abdominal infections are an important cause of morbidity and are
frequently associated with poor prognosis, particularly in higher risk patients. Well defined …

Objectives New antibacterial agents are required for the treatment of infections caused by
multidrug-resistant (MDR) Acinetobacter spp. Whether tigecycline constitutes an effective …